The global Circulating Tumor Cell Diagnostics market size was valued at US$ 4735 million in 2023. With growing demand in downstream market, the Circulating Tumor Cell Diagnostics is forecast to a readjusted size of US$ 8962.7 million by 2030 with a CAGR of 9.5% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cell Diagnostics market. Circulating Tumor Cell Diagnostics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Circulating Tumor Cell Diagnostics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Circulating Tumor Cell Diagnostics market.
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Circulating Tumor Cell Diagnostics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Circulating Tumor Cell Diagnostics market. It may include historical data, market segmentation by Type (e.g., CTC Enrichment, CTC Detection), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Circulating Tumor Cell Diagnostics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Circulating Tumor Cell Diagnostics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Circulating Tumor Cell Diagnostics industry. This include advancements in Circulating Tumor Cell Diagnostics technology, Circulating Tumor Cell Diagnostics new entrants, Circulating Tumor Cell Diagnostics new investment, and other innovations that are shaping the future of Circulating Tumor Cell Diagnostics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Circulating Tumor Cell Diagnostics market. It includes factors influencing customer ' purchasing decisions, preferences for Circulating Tumor Cell Diagnostics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Circulating Tumor Cell Diagnostics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Circulating Tumor Cell Diagnostics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Circulating Tumor Cell Diagnostics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Circulating Tumor Cell Diagnostics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Circulating Tumor Cell Diagnostics market.
Market Segmentation:
Circulating Tumor Cell Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
CTC Enrichment
CTC Detection
CTC Analysis
Segmentation by application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Circulating Tumor Cell Diagnostics Market Size 2019-2030
2.1.2 Circulating Tumor Cell Diagnostics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Circulating Tumor Cell Diagnostics Segment by Type
2.2.1 CTC Enrichment
2.2.2 CTC Detection
2.2.3 CTC Analysis
2.3 Circulating Tumor Cell Diagnostics Market Size by Type
2.3.1 Circulating Tumor Cell Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Circulating Tumor Cell Diagnostics Market Size Market Share by Type (2019-2024)
2.4 Circulating Tumor Cell Diagnostics Segment by Application
2.4.1 Tumorigenesis research
2.4.2 EMT biomarkers development
2.4.3 Cancer stem cell research
2.4.4 Others
2.5 Circulating Tumor Cell Diagnostics Market Size by Application
2.5.1 Circulating Tumor Cell Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Circulating Tumor Cell Diagnostics Market Size Market Share by Application (2019-2024)
3 Circulating Tumor Cell Diagnostics Market Size by Player
3.1 Circulating Tumor Cell Diagnostics Market Size Market Share by Players
3.1.1 Global Circulating Tumor Cell Diagnostics Revenue by Players (2019-2024)
3.1.2 Global Circulating Tumor Cell Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumor Cell Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Circulating Tumor Cell Diagnostics by Regions
4.1 Circulating Tumor Cell Diagnostics Market Size by Regions (2019-2024)
4.2 Americas Circulating Tumor Cell Diagnostics Market Size Growth (2019-2024)
4.3 APAC Circulating Tumor Cell Diagnostics Market Size Growth (2019-2024)
4.4 Europe Circulating Tumor Cell Diagnostics Market Size Growth (2019-2024)
4.5 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)
5.2 Americas Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)
5.3 Americas Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Circulating Tumor Cell Diagnostics Market Size by Region (2019-2024)
6.2 APAC Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)
6.3 APAC Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Circulating Tumor Cell Diagnostics by Country (2019-2024)
7.2 Europe Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)
7.3 Europe Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Circulating Tumor Cell Diagnostics by Region (2019-2024)
8.2 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)
8.3 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Circulating Tumor Cell Diagnostics Market Forecast
10.1 Global Circulating Tumor Cell Diagnostics Forecast by Regions (2025-2030)
10.1.1 Global Circulating Tumor Cell Diagnostics Forecast by Regions (2025-2030)
10.1.2 Americas Circulating Tumor Cell Diagnostics Forecast
10.1.3 APAC Circulating Tumor Cell Diagnostics Forecast
10.1.4 Europe Circulating Tumor Cell Diagnostics Forecast
10.1.5 Middle East & Africa Circulating Tumor Cell Diagnostics Forecast
10.2 Americas Circulating Tumor Cell Diagnostics Forecast by Country (2025-2030)
10.2.1 United States Circulating Tumor Cell Diagnostics Market Forecast
10.2.2 Canada Circulating Tumor Cell Diagnostics Market Forecast
10.2.3 Mexico Circulating Tumor Cell Diagnostics Market Forecast
10.2.4 Brazil Circulating Tumor Cell Diagnostics Market Forecast
10.3 APAC Circulating Tumor Cell Diagnostics Forecast by Region (2025-2030)
10.3.1 China Circulating Tumor Cell Diagnostics Market Forecast
10.3.2 Japan Circulating Tumor Cell Diagnostics Market Forecast
10.3.3 Korea Circulating Tumor Cell Diagnostics Market Forecast
10.3.4 Southeast Asia Circulating Tumor Cell Diagnostics Market Forecast
10.3.5 India Circulating Tumor Cell Diagnostics Market Forecast
10.3.6 Australia Circulating Tumor Cell Diagnostics Market Forecast
10.4 Europe Circulating Tumor Cell Diagnostics Forecast by Country (2025-2030)
10.4.1 Germany Circulating Tumor Cell Diagnostics Market Forecast
10.4.2 France Circulating Tumor Cell Diagnostics Market Forecast
10.4.3 UK Circulating Tumor Cell Diagnostics Market Forecast
10.4.4 Italy Circulating Tumor Cell Diagnostics Market Forecast
10.4.5 Russia Circulating Tumor Cell Diagnostics Market Forecast
10.5 Middle East & Africa Circulating Tumor Cell Diagnostics Forecast by Region (2025-2030)
10.5.1 Egypt Circulating Tumor Cell Diagnostics Market Forecast
10.5.2 South Africa Circulating Tumor Cell Diagnostics Market Forecast
10.5.3 Israel Circulating Tumor Cell Diagnostics Market Forecast
10.5.4 Turkey Circulating Tumor Cell Diagnostics Market Forecast
10.5.5 GCC Countries Circulating Tumor Cell Diagnostics Market Forecast
10.6 Global Circulating Tumor Cell Diagnostics Forecast by Type (2025-2030)
10.7 Global Circulating Tumor Cell Diagnostics Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Janssen Diagnostics
11.1.1 Janssen Diagnostics Company Information
11.1.2 Janssen Diagnostics Circulating Tumor Cell Diagnostics Product Offered
11.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Janssen Diagnostics Main Business Overview
11.1.5 Janssen Diagnostics Latest Developments
11.2 Advanced Cell Diagnostics
11.2.1 Advanced Cell Diagnostics Company Information
11.2.2 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product Offered
11.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Advanced Cell Diagnostics Main Business Overview
11.2.5 Advanced Cell Diagnostics Latest Developments
11.3 Aviva Biosciences
11.3.1 Aviva Biosciences Company Information
11.3.2 Aviva Biosciences Circulating Tumor Cell Diagnostics Product Offered
11.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Aviva Biosciences Main Business Overview
11.3.5 Aviva Biosciences Latest Developments
11.4 Biocept Inc
11.4.1 Biocept Inc Company Information
11.4.2 Biocept Inc Circulating Tumor Cell Diagnostics Product Offered
11.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Biocept Inc Main Business Overview
11.4.5 Biocept Inc Latest Developments
11.5 Biofluidica Inc.
11.5.1 Biofluidica Inc. Company Information
11.5.2 Biofluidica Inc. Circulating Tumor Cell Diagnostics Product Offered
11.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Biofluidica Inc. Main Business Overview
11.5.5 Biofluidica Inc. Latest Developments
11.6 CellTraffix Inc.
11.6.1 CellTraffix Inc. Company Information
11.6.2 CellTraffix Inc. Circulating Tumor Cell Diagnostics Product Offered
11.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 CellTraffix Inc. Main Business Overview
11.6.5 CellTraffix Inc. Latest Developments
11.7 Clearbridge BioMedics Pte Ltd
11.7.1 Clearbridge BioMedics Pte Ltd Company Information
11.7.2 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product Offered
11.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Clearbridge BioMedics Pte Ltd Main Business Overview
11.7.5 Clearbridge BioMedics Pte Ltd Latest Developments
11.8 Epic Sciences Inc.
11.8.1 Epic Sciences Inc. Company Information
11.8.2 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product Offered
11.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Epic Sciences Inc. Main Business Overview
11.8.5 Epic Sciences Inc. Latest Developments
11.9 Fluxion Biosciences Inc.
11.9.1 Fluxion Biosciences Inc. Company Information
11.9.2 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product Offered
11.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Fluxion Biosciences Inc. Main Business Overview
11.9.5 Fluxion Biosciences Inc. Latest Developments
11.10 ScreenCell
11.10.1 ScreenCell Company Information
11.10.2 ScreenCell Circulating Tumor Cell Diagnostics Product Offered
11.10.3 ScreenCell Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 ScreenCell Main Business Overview
11.10.5 ScreenCell Latest Developments
11.11 Silicon Biosystems
11.11.1 Silicon Biosystems Company Information
11.11.2 Silicon Biosystems Circulating Tumor Cell Diagnostics Product Offered
11.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Silicon Biosystems Main Business Overview
11.11.5 Silicon Biosystems Latest Developments
11.12 Sysmex Corporation
11.12.1 Sysmex Corporation Company Information
11.12.2 Sysmex Corporation Circulating Tumor Cell Diagnostics Product Offered
11.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Sysmex Corporation Main Business Overview
11.12.5 Sysmex Corporation Latest Developments
11.13 Greiner Bio-One GmbH
11.13.1 Greiner Bio-One GmbH Company Information
11.13.2 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product Offered
11.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Greiner Bio-One GmbH Main Business Overview
11.13.5 Greiner Bio-One GmbH Latest Developments
11.14 AdnaGen AG
11.14.1 AdnaGen AG Company Information
11.14.2 AdnaGen AG Circulating Tumor Cell Diagnostics Product Offered
11.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 AdnaGen AG Main Business Overview
11.14.5 AdnaGen AG Latest Developments
11.15 Apocell Inc
11.15.1 Apocell Inc Company Information
11.15.2 Apocell Inc Circulating Tumor Cell Diagnostics Product Offered
11.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Apocell Inc Main Business Overview
11.15.5 Apocell Inc Latest Developments
11.16 Biocep Ltd
11.16.1 Biocep Ltd Company Information
11.16.2 Biocep Ltd Circulating Tumor Cell Diagnostics Product Offered
11.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Biocep Ltd Main Business Overview
11.16.5 Biocep Ltd Latest Developments
11.17 Canopus Bioscience Ltd
11.17.1 Canopus Bioscience Ltd Company Information
11.17.2 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product Offered
11.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Canopus Bioscience Ltd Main Business Overview
11.17.5 Canopus Bioscience Ltd Latest Developments
11.18 Creatv Microtech Inc
11.18.1 Creatv Microtech Inc Company Information
11.18.2 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product Offered
11.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Creatv Microtech Inc Main Business Overview
11.18.5 Creatv Microtech Inc Latest Developments
11.19 Ikonisys Inc
11.19.1 Ikonisys Inc Company Information
11.19.2 Ikonisys Inc Circulating Tumor Cell Diagnostics Product Offered
11.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Ikonisys Inc Main Business Overview
11.19.5 Ikonisys Inc Latest Developments
11.20 IV Diagnostics Inc
11.20.1 IV Diagnostics Inc Company Information
11.20.2 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product Offered
11.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 IV Diagnostics Inc Main Business Overview
11.20.5 IV Diagnostics Inc Latest Developments
11.21 Miltenyi Biotech GmbH
11.21.1 Miltenyi Biotech GmbH Company Information
11.21.2 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product Offered
11.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 Miltenyi Biotech GmbH Main Business Overview
11.21.5 Miltenyi Biotech GmbH Latest Developments
11.22 Nanostring Technologies Inc
11.22.1 Nanostring Technologies Inc Company Information
11.22.2 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product Offered
11.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 Nanostring Technologies Inc Main Business Overview
11.22.5 Nanostring Technologies Inc Latest Developments
11.23 Rarecells Diagnostics.
11.23.1 Rarecells Diagnostics. Company Information
11.23.2 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product Offered
11.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.23.4 Rarecells Diagnostics. Main Business Overview
11.23.5 Rarecells Diagnostics. Latest Developments
11.24 Vitatex Inc
11.24.1 Vitatex Inc Company Information
11.24.2 Vitatex Inc Circulating Tumor Cell Diagnostics Product Offered
11.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
11.24.4 Vitatex Inc Main Business Overview
11.24.5 Vitatex Inc Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
